Fast on-rates of chimeric antigen receptors enhance the sensitivity to peptide MHC via antigen rebinding.

ABSTRACT: Chimeric antigen receptor (CAR) is a synthetic receptor that induces T cell-mediated lysis of abnormal cells. As cancer driver proteins are present at low levels on the cell surface, they can cause weak CAR reactivity, resulting in antigen sensitivity defects and consequently limited therapeutic efficacy. Although affinity maturation enhances the efficacy of CAR-T cell therapy, it causes off-target cross-reactions resulting in adverse effects. Preferentially expressed antigen in melanoma (PRAME) is an intracellular oncoprotein that is overexpressed in various tumors and restricted in normal tissues, except the testis. Therefore, PRAME could be an ideal target for cancer immunotherapy. In this study, we developed an experimental CAR system comprising six single-chain variable fragments that

SUBMITTER: Hiratsuka H 

PROVIDER: S-EPMC11407991 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature